Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT-IKK/STAT3 Axis

Xiaoping Wang1, Weili Li2, Yawen Zhang1

  • 1School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.

Insights

Calycosin (Cal) reduces heart failure by inhibiting inflammation and fibrosis. This natural compound activates the PI3K-AKT pathway, improving cardiac function after myocardial infarction in rats.

Area of Science:

  • Cardiovascular Biology
  • Pharmacology
  • Molecular Medicine

Background:

  • Inflammation and fibrosis are key drivers of heart failure (HF) progression.
  • Calycosin (Cal), from Astragalus mongholicus, shows potential for cardiac dysfunction post-myocardial infarction (MI).
  • Mechanisms of Cal's effects on MI-induced inflammation and fibrosis require clarification.

Purpose of the Study:

  • To investigate Cal's role in mitigating heart failure.
  • To elucidate the precise molecular mechanisms underlying Cal's cardioprotective effects.

Main Methods:

  • Established rat model of myocardial infarction (MI) via left anterior descending artery ligation.
  • Assessed Cal's cardioprotective effects using echocardiography and histological analysis.
  • Employed RNA-sequencing for pathway and gene discovery, alongside in vitro models (H9C2 cells, cardiac fibroblasts) to confirm mechanisms.

Main Results:

  • Cal significantly improved cardiac function in MI rats, evidenced by echocardiography.
  • Cal downregulated inflammatory markers (p-IKKα/β, p-NFκB, TNFα) and attenuated cardiac fibrosis (collagen I & III).
  • Mechanistic studies revealed Cal activates the PI3K-AKT pathway, crucial for its anti-inflammatory and anti-fibrotic actions.

Conclusions:

  • Calycosin effectively inhibits inflammation and fibrosis in post-MI heart failure.
  • The cardioprotective effects of Cal are mediated by the activation of the PI3K-AKT signaling pathway.
  • Cal demonstrates therapeutic potential for treating heart failure resulting from myocardial infarction.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.5K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
777
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
543
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
271
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
5.3K